Thymosin Alpha-1 vs Humanin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Thymosin Alpha-1
Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a crucial role in immune system modulation. It is approved in over 35 countries for various conditions including hepatitis B and C.
Full details →Humanin
Humanin is a mitochondrial-derived peptide with potent cytoprotective effects. Discovered in 2001, it has shown promise in protecting against age-related diseases including Alzheimer's, cardiovascular disease, and diabetes.
Full details →Side-by-Side Comparison
| Aspect | Thymosin Alpha-1 | Humanin |
|---|---|---|
| Mechanism | Enhances T-cell function and maturation, stimulates dendritic cell activity, and modulates cytokine production. Promotes the differentiation of stem cells into mature T lymphocytes. | Binds to IGFBP-3 and BAX, inhibiting apoptosis. Activates STAT3 signaling and enhances cellular survival under stress. Protects mitochondrial function and reduces oxidative stress. |
| Typical Dosage | Clinical dosing typically ranges from 1.6mg to 6.4mg administered subcutaneously 2-3 times weekly. Research protocols may vary. | Research protocols vary widely. Studies have used doses from micrograms to milligrams depending on the analog and route. HNG (S14G-Humanin) is a more potent analog. |
| Administration | Subcutaneous injection. Often used in cycles or as part of comprehensive immune support protocols. | Subcutaneous or intraperitoneal injection in research. Various analogs exist with different potencies and stabilities. |
| Side Effects | Generally well-tolerated. Rare side effects include injection site reactions, mild flu-like symptoms, and temporary fatigue. | Limited human data. Generally well-tolerated in animal studies. May affect glucose metabolism. |
| Best For |